Alzamend Neuro Adds Healthy Subjects to Ongoing Mid-Stage Alzheimer's Trial

Vandana Singh
1 min read
0
In this article:

  • Alzamend Neuro Inc (NASDAQ: ALZN) has dosed its first healthy adult subject in its Phase 2A multiple ascending dose (MAD) study of AL001 in subjects with dementia related to Alzheimer's.

  • This blinded, placebo-controlled trial (AL001-02) was initiated in May 2022 and is designed to evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions and determine the maximum tolerated dose.

  • Alzamend is also pursuing AL001 for bipolar disorder, major depressive disorder, and post-traumatic stress disorder.

  • Related: Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study.

  • Based upon a recommendation by the FDA after its review and commentary on Alzamend's pre-investigational new drug briefing package for the development of AL001, the ongoing clinical trial in Alzheimer's patients has been expanded.

  • Alzamend will test AL001 in four healthy adult and elderly adult cohorts of eight subjects under MAD conditions.

  • AL001 is a novel lithium-salicylate-L-proline engineered ionic cocrystal lithium delivery system.

  • Price Action: ALZN shares are up 0.01% at $1.3801 on the last check Wednesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories